ConductScience.org, home

Trial · NCT07912242

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in Western Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ)Baseline (approximately 3 months post-stroke) and 6 months post-stroke
The WAB-R AQ is a composite measure of overall language impairment, with scores ranging from 0 to 100; higher scores indicate milder aphasia (better outcome). Change from baseline to 6 months post-stroke is compared between the early intervention group (after treatment) and the wait-list group (before treatment).
PrimaryMean Absolute Error Between Predicted and Observed 12-Month Western Aphasia Battery-Revised Aphasia Quotient12 months post-stroke
Mean absolute difference, in WAB-R AQ points (scale 0 to 100), between the machine learning model's predicted 12-month Western Aphasia Battery-Revised Aphasia Quotient (generated from acute-phase data) and the observed 12-month score. Lower values indicate more accurate prediction.
SecondaryPercentage of Treatment Items Produced CorrectlyDuring treatment, up to one week post final treatment session (about 4 to 6 weeks after treatment starts)Percentage of items trained during treatment that are produced correctly, scored 0 to 100%; higher values indicate better performance.
SecondaryChange in Number of Content Units in Picture DescriptionBaseline (approximately 3 months post-stroke) and 6 months post-stroke
Total number of content units (accurate, relevant pieces of information) produced when describing the Modern Cookie Theft picture and the Precarious Painter picture. Higher values indicate more informative discourse.
SecondaryChange in Syllables per Content Unit in Picture DescriptionBaseline (approximately 3 months post-stroke) and 6 months post-strokeNumber of syllables produced per content unit in the same picture descriptions
SecondaryChange in Communication Activities of Daily Living, Third Edition (CADL-3) Total ScoreBaseline (approximately 3 months post-stroke) and 6 months post-stroke
The Communication Activities of Daily Living, Third Edition measures everyday functional communication in people with aphasia. Total raw score ranges from 0 to 100; higher scores indicate better functional communication.
SecondaryChange in General Health Questionnaire (GHQ) Total ScoreBaseline (approximately 3 months post-stroke) and 6 months post-stroke
The General Health Questionnaire (Goldberg and Hillier) measures psychological distress and emotional well-being. Items are rated using 0 to 3 Likert scale, giving a total score from 0 to 84; higher scores indicate greater psychological distress (worse outcome).
SecondaryChange in Stroke and Aphasia Quality of Life Scale (SAQOL-39) Mean ScoreBaseline (approximately 3 months post-stroke) and 6 months post-strokeThe Stroke and Aphasia Quality of Life Scale-39 measures health-related quality of life after stroke and aphasia. Mean score ranges from 1 to 5; higher scores indicate better quality of life.
SecondaryChange in Resting-State Functional Connectivity Between Cortical Language Regions and the Right CerebellumBaseline (approximately 3 months post-stroke), 6 months, and 9 months post-stroke
Resting-state functional connectivity (correlation coefficient of oxygenated hemoglobin signals) between cortical language regions and the right cerebellum, measured with functional near-infrared spectroscopy (fNIRS). Higher values indicate stronger connectivity.
OtherWestern Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ) at 9 Months Post-Stroke9 months post-stroke
The WAB-R AQ is a composite measure of overall language impairment (range 0 to 100; higher scores indicate milder aphasia). Compared between groups to explore the effect of treatment timing (treatment starting about 3 versus 6 months post-stroke).
OtherWestern Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ) at 12 Months Post-Stroke12 months post-strokeThe WAB-R AQ is a composite measure of overall language impairment (range 0 to 100; higher scores indicate milder aphasia). Used to assess durability of treatment effects in all participants.

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07912242/registered